Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance

References

• Almalik A, Karimi S, Ouasti S, et al. (2013). Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles. Biomaterials 34:5369–80.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ghosh A, Maiti S, et al. (2020). Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer. J Control Release 322:357–74.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L, et al. (2016). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 370:153–64.
   PubMed Web of Science ®Google Scholar
• Cheng C, Meng Y, Zhang Z, et al. (2018). Tumoral acidic pH-responsive cis-diaminodichloroplatinum-incorporated Cy5.5-PEG- g-A-HA nanoparticles for targeting delivery of CDDP against cervical cancer. ACS Appl Mater Interf 10:26882–92.
   PubMed Web of Science ®Google Scholar
• Du C, Qi Y, Zhang Y, et al. (2018). Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation. ACS Nano 12:10785–96.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu J, Xie F, et al. (2019). Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomed 14:9199–216.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
   PubMed Web of Science ®Google Scholar
• Gupta B, Ramasamy T, Poudel BK, et al. (2017). Development of bioactive PEGylated nanostructured platforms for sequential delivery of doxorubicin and imatinib to overcome drug resistance in metastatic tumors. ACS Appl Mater Interf 9:9280–90.
   PubMed Web of Science ®Google Scholar
• Horinkova J, Sima M, Slanar O. (2019). Pharmacokinetics of dasatinib. Prague Med Rep 120:52–63.
   PubMedGoogle Scholar
• Huo Q, Zhu J, Niu Y, et al. (2017). pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer. Int J Nanomed 12:8631–47.
   PubMed Web of Science ®Google Scholar
• Karousou E, Misra S, Ghatak S, et al. (2017). Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol 59:3–22.
   PubMed Web of Science ®Google Scholar
• Koshkin V, Yang BB, Krylov SN. (2013). Kinetics of MDR transport in tumor-initiating cells. PLoS One 8:e79222.
   PubMed Web of Science ®Google Scholar
• Levêque D, Becker G, Bilger K, Natarajan-Amé S. (2020). Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet 59:849–56.
   PubMed Web of Science ®Google Scholar
• Li M, Jin S, Cao Y, et al. (2021). Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway. Cancer Cell Int 21:19.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu X, Zhang X, et al. (2017). Tumor-specific multiple stimuli-activated dendrimeric nanoassemblies with metabolic blockade surmount chemotherapy resistance. ACS Nano 11:416–29.
   PubMed Web of Science ®Google Scholar
• Lindauer M, Hochhaus A. [J]. (2010). Dasatinib. Recent Results Cancer Res 184:83–102.
   PubMedGoogle Scholar
• Lindauer M, Hochhaus A. [J]. (2018). Dasatinib. Recent Results Cancer Res 212:29–68.
   PubMedGoogle Scholar
• Montero JC, Seoane S, Ocana A, et al. (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17:5546–52.
   PubMed Web of Science ®Google Scholar
• Negi LM, Talegaonkar S, Jaggi M, et al. (2019). Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an in-vitro, in-vivo and mechanistic investigation. J Drug Target 27:183–92.
   PubMed Web of Science ®Google Scholar
• Niza E, Nieto-Jimenez C, Noblejas-Lopez M. (2019). Poly(cyclohexene phthalate) nanoparticles for controlled dasatinib delivery in breast cancer therapy. Nanomaterials (Basel) 9(9):1208.
   Google Scholar
• Popova M, Mihaylova R, Momekov G, et al. (2019). Verapamil delivery systems on the basis of mesoporous ZSM-5/KIT-6 and ZSM-5/SBA-15 polymer nanocomposites as a potential tool to overcome MDR in cancer cells. Eur J Pharm Biopharm 142:460–72.
   PubMed Web of Science ®Google Scholar
• Priya DK, Fang H, Ramya DD, et al. (2021). pH-sensitive chitosan nanoparticles loaded with dolutegravir as milk and food admixture for paediatric anti-HIV therapy. Carbohydr Polym 256:117440.
   PubMed Web of Science ®Google Scholar
• Ren X, Wang N, Zhou Y. (2021). An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. Acta Biomater. 124:179–90.
   PubMed Web of Science ®Google Scholar
• Singh MS, Tammam SN, Shetab BM, et al. (2017). MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res 126:2–30.
   PubMed Web of Science ®Google Scholar
• Tao R, Wang C, Lu Y, et al. (2020). Characterization and cytotoxicity of polyprenol lipid and vitamin E-TPGS hybrid nanoparticles for betulinic acid and low-substituted hydroxyl fullerenol in MHCC97H and L02 cells. Int J Nanomed 15:2733–49.
   PubMed Web of Science ®Google Scholar
• Tian H, Zhang M, Jin G, et al. (2021). Cu-MOF chemodynamic nanoplatform via modulating glutathione and H2O2 in tumor microenvironment for amplified cancer therapy. J Colloid Interface Sci 587:358–66.
   PubMed Web of Science ®Google Scholar
• Tian Y, Li JC, Zhu JX, et al. (2017). Folic acid-targeted etoposide cubosomes for theranostic application of cancer cell imaging and therapy. Med Sci Monit 23:2426–35.
   PubMed Web of Science ®Google Scholar
• Tirella A, Kloc-Muniak K, Good L, et al. (2019). CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment. Int J Pharm 561:114–23.
   PubMed Web of Science ®Google Scholar
• Trujillo-Nolasco RM, Morales-Avila E, Ocampo-Garcia BE, et al. (2019). Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. Mater Sci Eng C Mater Biol Appl 103:109766.
   PubMed Web of Science ®Google Scholar
• Wan F, Bohr SS-R, Kłodzińska SN, et al. (2020). Ultrasmall TPGS-PLGA hybrid nanoparticles for site-specific delivery of antibiotics into Pseudomonas aeruginosa biofilms in lungs. ACS Appl Mater Interfaces 12:380–9.
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhang DD, Kong YY, et al. (2016). CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells. Colloids Surf B Biointerf 145:716–27.
   PubMed Web of Science ®Google Scholar
• Williams K, Motiani K, Giridhar PV, et al. (2013). CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 238:324–38.
   PubMed Web of Science ®Google Scholar
• Xu C, Xu J, Zheng Y, et al. (2020). Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer. J Mater Chem B 8:2726–37.
   PubMed Web of Science ®Google Scholar
• Yao Q, Liu Y, Kou L, et al. (2019). Tumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles. Nanomedicine 19:71–80.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang N, Li Q, et al. (2021). A two-pronged photodynamic nanodrug to prevent metastasis of basal-like breast cancer. Chem Commun (Camb) 57:2305–8.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ren X, Hou Z, et al. (2021). Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation. Nanoscale Horiz 6:120–31.
   PubMed Web of Science ®Google Scholar